The incidence of end-stage renal disease (ESRD) is rising worldwide, accompanied by corresponding increases in the risk of morbidity and mortality. Underlying this trend are increasing rates of hypertension and diabetes mellitus, the two most common causes of ESRD. In addition to the adverse haemodynamic effects of hypertension on the kidney, elevated blood pressure (BP) can activate components of the renin-angiotensinaldosterone system (RAAS), which, in turn, activate mediators of inflammation, oxidative stress, cell growth, and matrix accumulation. Lowering BP reduces the risk of cardiovascular events and renal damage. Accumulating evidence from clinical and laboratory studies suggests that interrupting the RAAS with therapies such as angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone receptor blockers can interfere with the mechanisms that promote diabetic and non-diabetic renal damage. Moreover, clinical trials of RAAS blockade have demonstrated reductions in microalbuminuria, a predictor of increased cardiorenal risk and overt nephropathy in patients with and without diabetes and/or hypertension. In this way, agents that block the RAAS should be considered the drugs of first choice as they provide enhanced renoprotection compared with other classes of antihypertensive agents such as calcium channel blockers and b-blockers.
Introduction
End-stage renal disease (ESRD) is a major public health concern, and the incidence of ESRD is increasing worldwide. 1 Hypertension is the second leading cause of ESRD in the United States and is also a major contributor to diabetic renal disease, which is the leading cause of ESRD.
2, 3 The interactions between hypertension and renal disease are complex. Nephropathy contributes to the development and severity of hypertension, while elevated blood pressure (BP) accelerates the course of nephropathy. Moreover, hypertension contributes to the development of multiple cardiovascular risk factors. 4, 5 Diabetes mellitus and hypertension are similarly interrelated. Diabetes is associated with a high prevalence of hypertension, while hypertension increases the risk of developing diabetes and diabetes-related complications. 5 The risk of ESRD is five to six times higher in persons with both diabetes and hypertension than in persons with hypertension alone. 6 Indeed, target BP levels are lower for diabetic patients compared with non-diabetic persons in recognition of both the additional cardiovascular risk conferred by diabetes and the proven risk reduction associated with the lower target BP. 3, [7] [8] [9] This article first examines the pathophysiology of renal disease associated with hypertension and diabetes, with an emphasis on the role of the renin-angiotensin-aldosterone system (RAAS) in the development of disease. We then summarize clinical trial evidence for the benefits of agents that inhibit the RAAS in hypertensive and normotensive patients both with and without diabetes. The clinical trials discussed were identified by performing a comprehensive search of the MEDLINE database for randomized, controlled trials published since 2000 and performed in human subjects. Trials were limited to those with primary outcomes involving renal parameters and utilizing therapeutic interventions targeting the RAAS. The following search terms were used: nephropathy, proteinuria, albuminuria, microalbuminuria, renal disease, angiotensin II/antagonists and inhibitors, angioten-sin-converting enzyme (ACE) inhibitors, and angiotensin II type I receptor blockers. Abstracts of the citations yielded by this search strategy were reviewed, and some trials were eliminated for reasons of space because of the small numbers of patients or because the results duplicated those of other studies. The resulting trials list was then supplemented by reviewing reference lists of clinical guidelines and meta-analyses.
Pathophysiology
Haemodynamic and metabolic perturbations contribute to the development and progression of renal disease. Hypertension, both systemic and intraglomerular, is a key factor in diabetic and non-diabetic nephropathy. 4, 10, 11 Under normal conditions, an autoregulatory mechanism protects the renal microvasculature from the effects of increasing arterial pressure. If this protective mechanism becomes impaired, as in diabetes mellitus, arterial hypertension can damage the kidney. The continued absence of the autoregulatory response further exacerbates pressure-induced effects, leading to glomerulopathy. In the early phase of kidney disease, the impaired autoregulatory system results in afferent arteriolar vasodilation and impaired pressure-induced vasoconstriction. 12 As renal disease progresses, the effect of systemic hypertension on glomerular pressure and renal flow contributes to the development of proteinuria and progressive renal failure. 4, 13 Multiple factors influence haemodynamic mediators of renal disease (Table 1) , including components of the RAAS such as angiotensin II, which can induce systemic and glomerular hypertension. 12 Angiotensin II induces intrarenal vasoconstriction, reducing renal blood flow and resulting in ischaemia-induced injury, and also contributes to proteinuria (resulting in tubular injury). Studies in models of normotension and hypertension show that angiotensin II increases resistance in both afferent and efferent renal arterioles in a dose-dependent manner, which may lead to reductions in single-nephron glomerular filtration rate (GFR) and glomerular plasma flow.
14 Further, ACE promotes degradation of bradykinin and downregulates the endotheliumderived vasodilator nitric oxide (NO). NO plays an important role in glomerular vascular haemodynamics, regulating vascular tone of afferent glomerular arterioles, and, to a lesser degree, efferent arterioles. 15 Indeed, in early phase hypertension, NO appears to be the central mechanism that preserves renal blood flow in the afferent arteriole and GFR. 14, 15 Following blockade of the RAAS, the increase in GFR and renal plasma flow indicates that high intrarenal levels of angiotensin II are detrimental to the renal pre-glomerular microvasculature. Further, RAAS blockade reduces postglomerular resistance, which lowers intraglomerular pressure and is protective of renal injury. 16 In contrast, experimental models have found that dihydropyridine calcium channel blockers (CCBs) can impair the protective autoregulatory vasoconstrictor response of the afferent arteriole, thus exaggerating glomerular capillary exposure to systemic hypertension. 17 Over time, this exposure might result in glomerular capillary hypertension, hyperfiltration, accelerated glomerulosclerosis, and progression of kidney disease. [17] [18] [19] Angiotensin II also contributes to renal disease by non-haemodynamic mechanisms (Figure 1 ). These mechanisms can trigger the release of mediators of oxidative stress, inflammatory mediators, and other growth factors, which stimulate extracellular matrix accumulation, cell proliferation, and hypertrophy. 12, 13, 20 Angiotensin II and mechanical stretch upregulate glucose transporter-1 (GLUT-1) via induction of transforming growth factor-b (TGF-b), 21 which also mediates production of extracellular matrix. 22 In addition, glucose uptake is increased along with GLUT-1 levels. 23 In vitro findings indicate that high levels of glucose promote cell hypertrophy and accumulation of extracellular matrix, a key histologic finding in diabetic nephropathy. 24 Experimental induction of hypertension with angiotensin II results in downstream activation of mitogen-activated protein kinases, which is associated with activation of mediators of renal injury, including activating protein-1 (AP-1). AP-1, in turn, stimulates production of TGF-b, leading to cell growth and proliferation. 25 TGF-b and other growth factors and matrix proteins are important contributors to vascular and renal hypertrophy. TGF-b is upregulated in response to tissue injury and is implicated in tissue fibrosis associated with diabetic renal disease 26 and with hypertension. 27 Monocyte chemoattractant protein-1 (MCP-1), a key inflammatory mediator in the pathogenesis of nephropathy, has been implicated in matrix accumulation and diabetic nephropathy; MCP-1 is also increased in angiotensin-induced hypertension. 28 Elevated intraluminal pressure can also lead to downregulation of tissue plasminogen activator, a promoter of fibrinolysis/thrombolysis, which is impaired in patients with hypertension. 29 Angiotensin II also increases production of plasminogen activator inhibitor-1, which is both a major inhibitor of fibrinolysis and is antiproteolytic, thus promoting matrix accumulation. 30 Aldosterone independently contributes to renal injury, as well. Pathways shown to promote aldosterone-induced renal damage include generation of inflammatory cytokines such as MCP-1 and TGF-b, increased production of plasminogen activator inhibitor-1, generation of reactive oxygen species, and upregulation of angiotensin II type I receptors, which facilitate the deleterious effects of angiotensin II.
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Benefits of aggressive BP control
Given the importance of hypertension in renal disease, it is not surprising that antihypertensive therapy has demonstrated benefits in patients with diabetes and/or renal damage. Studies have established the effectiveness of tight BP control for reducing the risk of microalbuminuria in patients with type I or type II diabetes. 9, 34 Microalbuminuria in hypertension is a recognized predictor of ESRD, as well as cardiovascular events and early mortality, in patients with and without diabetes. [35] [36] [37] [38] [39] [40] Current guidelines recommend BP levels o130/ 80 mm Hg in patients with renal disease. 3, 41 Recommended levels are even more aggressive, o125/ 75 mm Hg, in the presence of renal disease and proteinuria 41 g/day. 3, 41 No clinical trial has yet clearly established whether achieving such aggressive BP targets lowers the risk of ESRD in diabetic or non-diabetic renal disease. Although some trials have failed to show a significant benefit for tight vs moderate BP control, 42, 43 other trials provide evidence in support of these guidelines.
In the MDRD study, 10 the decline in GFR in subjects with renal disease of various aetiologies was slower in subjects randomly assigned to achieve a low BP goal (mean arterial pressure p92 mm Hg for patients aged p60 years and p98 mm Hg in patients aged X61 years) than in those assigned to a usual BP goal (p107 and p113 mm Hg in younger and older patients, respectively). The relationship between aggressive BP control and renoprotection was stronger in patients with greater baseline proteinuria. 10 Long-term follow-up results from this study also showed that the lower BP delayed the progression to kidney failure and reduced the composite outcome of kidney failure and all-cause mortality. 44 However, limitations of this study included a lack of BP measurements at some points of the follow-up. 44 In a recently published retrospective analysis of the Irbesartan Diabetic Nephropathy Trial (IDNT), achieved systolic BP 4149 mm Hg was associated with a 2.2-fold increased risk for doubling of serum creatinine or ESRD compared with systolic BP o134 mm Hg. Importantly, the results suggest that a progressive lowering of systolic BP to 120 mm Hg is associated with improved renal and patient survival. An additional renoprotective effect of irbesartan, independent of achieved systolic BP, was observed down to 120 mm Hg, and this effect was independent of baseline renal function. However, the results also suggest that all-cause mortality may increase below this threshold. 45 The Hypertension Optimal Treatment (HOT) trial and United Kingdom Prospective Diabetes Study (UKPDS) were the first large trials to demonstrate that aggressive BP control reduced the risk of cardiovascular events in diabetic patients. 9, 46 In the UKPDS, tight BP control (mean 144/82 mm Hg) was associated with a 24% reduction in risk of any diabetes-related end point, compared with less tight BP control (mean 154/87 mm Hg). 9 For example, the study found a 29% lower risk of microalbuminuria at 6 years (P ¼ 0.009). There was also a Figure 1 Inflammation, matrix accumulation, and fibrosis in the development of nephropathy. Angiotensin II plus glucose leads to inflammation and subsequently fibrosis. Angiotensin II also induces mediators of oxidative stress and fibrosis, leading to renal damage. AP-1 ¼ activating protein 1; AT-1 ¼ angiotensin II type I receptor; AGEs ¼ advanced glycosylation end products; ERK ¼ extracellular signal-regulated kinases; GLUT-1 ¼ glucose transporter-1; HBP ¼ high blood pressure; JAK ¼ Janus kinases; MAPK ¼ mitogen-activated protein kinases; MCP-1 ¼ monocyte chemoattractant protein 1; NF-kB ¼ nuclear factor kB; PAI39% lower risk of proteinuria (P ¼ 0.061) with tight BP control compared with moderate BP control, although this difference was not statistically significant. 9 Tight BP control was shown to be more effective in decreasing risk in this population than glycaemic control. 9 A consensus report found that there is a linear relationship between achieved BP and rate of decline in renal function. This finding was consistent across clinical studies involving either diabetic or non-diabetic patients. 5 The RAAS as a therapeutic target
The importance of the RAAS in hypertension and renal disease provides a strong rationale for the use of agents that inhibit this system in patients who have or are at risk for kidney disease. ACE inhibitors and angiotensin II receptor blockers (ARBs) have demonstrated renoprotection in diabetic and nondiabetic patients with and without hypertension.
3,41,46-50 Hence, ACE inhibitors and ARBs are recommended by the American Diabetes Association as first-line antihypertensive therapies for patients with diabetes. 7 The renoprotective effects of ACE inhibitors and ARBs, including reduction of albuminuria and improvements in glomerular histology, 4, 51 appear to be at least partly independent of their BP-lowering effects. 40, 52 Studies in animal models of diabetes or hypertension suggest that the therapeutic benefits of ARBs and ACE inhibitors might be mediated through a number of mechanisms, including suppression of MCP-1, 28 inhibition of collagen synthesis and stimulation of metalloproteinase activity, 27 prevention of loss of glomerular nephrin, 53 and prevention of overexpression of TGF-b1 and type IV collagen. 54 Evidence also suggests that improved glomerular permselectivity may contribute to renoprotection. 55 
Clinical evidence of benefits of RAAS inhibition in patients with diabetes mellitus
There is convincing evidence that ACE inhibitors and ARBs inhibit development or progression of microalbuminuria and albuminuria in patients with diabetes. 34, 40, [46] [47] [48] [56] [57] [58] [59] Clinical trials, grouped by the degree of albuminuria, demonstrating the beneficial effects of RAAS inhibition on renal end points in patients with diabetes mellitus are summarized in Table 2 . 34, 40, 42, 48, 49, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] Normoalbuminuria The Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) is the only primary prevention study to date to demonstrate that the development of microalbuminuria can be prevented by the use of an ACE inhibitor alone or in combination with a CCB in hypertensive normoalbuminuric patients with type II diabetes. 59 
Microalbuminuria
In type I diabetes, the EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes (EUCLID) study 34 showed that lisinopril significantly delayed the increase in urinary albumin excretion rate (UAER) compared with placebo in normotensive patients. Most of the treatment effect was concentrated in subjects with microalbuminuria (UAER X20 to p250 mg/min) at baseline; only a minimal effect was seen in patients with normoalbuminuria. 34 A meta-analysis of 12 placebo-controlled trials (including EUCLID) in normotensive patients with type I diabetes and baseline microalbuminuria showed that ACE inhibitor therapy was associated with a 62% reduction in the risk of progression from microalbuminuria to macroalbuminuria and a 300% increase in the likelihood of regression to normoalbuminuria. 56 Again, the estimated treatment effect was greater in patients with a higher baseline UAER. In type II diabetes, several studies have demonstrated that ARBs and ACE inhibitors can reduce the progression of microalbuminuria, and some of these trials will be discussed in more detail later in this article.
40,58,63
Macroalbuminuria
In patients with type I diabetes and proteinuria, captopril reduced the risk of progression of nephropathy by 48% vs placebo; the risk reduction was greater in patients with higher baseline serum creatinine levels. 48 Captopril also halved the risk of the combined end point of death, dialysis, or transplantation in these patients. These results were independent of the small BP differences between study arms. 48 The IDNT, 49, 62 in patients with type II diabetes and proteinuria, demonstrated that a reduction in albuminuria during antihypertensive treatment is associated with reduction in progression of nephropathy and development of ESRD. Indeed, IDNT found that halving proteinuria by 12 months of treatment reduced the risk of kidney failure by half.
An ACE inhibitor (ramipril) reduced the risk of cardiovascular events in diabetic patients with microalbuminuria in the Heart Outcomes Prevention Evaluation (HOPE). 72 Results from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study 73 and from IDNT 62 suggest that a reduction in albuminuria during antihypertensive treatment is associated with a reduction in the risk of cardiovascular events as well as reduction in progression of nephropathy and development of ESRD.
Evidence from controlled clinical trials clearly supports the use of ACE inhibitors or ARBs in patients with diabetic nephropathy. The most robust Evidence for renoprotection by blockade of the RAAS J Karalliedde and G Viberti 
years (mean)
Losartan k RR of doubling of serum creatinine by 25% (P ¼ 0.006) and of ESRD by 28% (P ¼ 0.002), but no effect on all-cause mortality trial evidence supports the use of ACE inhibitors in type I diabetic nephropathy and ARBs in type II diabetic nephropathy. However, a lack of comparative studies leaves unresolved whether ACE inhibitors are equivalent to ARBs, although one comparative study in subjects with type II diabetes (the majority with microalbuminuria) suggests that ACE inhibitors are not inferior to ARBs. 61 Reviews suggest that in patients with either type I or type II diabetes, inhibitors of the RAAS need to be used early, and that these agents confer greater renoprotection for equivalent BP control. 74, 75 RAAS blockade compared with calcium channel blockade in diabetic renal disease CCBs are effective antihypertensive agents, but their effects on parameters of kidney function have been inconsistent. Some studies have shown beneficial effects similar to those seen with ACE inhibitors, 42, 63, 67 whereas others have shown either no benefit or adverse effects of CCBs compared with ACE inhibitors or ARBs. 76, 77 Normoalbuminuria. The BENEDICT trial demonstrated that in subjects with type II diabetes and hypertension but with normoalbuminuria, the use of ACE inhibitor (trandolapril) alone or in combination with a CCB (verapamil) decreased the incidence of microalbuminuria to a similar extent. The effect of verapamil alone was similar to that of placebo. 59 Microalbuminuria. ARBs delay progression to nephropathy in patients with type II diabetes, microalbuminuria, and hypertension. The Microalbuminuria Reduction with Valsartan (MARVAL) study 40 compared the effect of valsartan with amlodipine in hypertensive and normotensive patients with type II diabetes and microalbuminuria. Although the BP-lowering effect of the two drugs was similar, at 6 months the decrease from baseline in UAER was significantly greater with valsartan (44%) than with amlodipine (8%; Po0.001). Results were similar in the hypertensive and normotensive subgroups. The frequency of regression to normoalbuminuria was also significantly greater for valsartan (29.9%) than for amlodipine (14.5%; P ¼ 0.001). 40 One possible explanation for the benefit conferred by valsartan was investigated in a study of subjects with mild-to-moderate hypertension in which valsartan maintained the GFR and the glomerular hydrostatic pressure. 78 In contrast, amlodipine was associated with glomerular hyperfiltration and an increase in glomerular hydrostatic pressure. BP control was similar with both treatments. 78 In the Irbesartan in Patients with Type II Diabetes and Microalbuminuria (IRMA-II) study, 58 irbesartan (150 or 300 mg daily) reduced the risk of progression to clinical proteinuria by 39% (P ¼ 0.08) and 70% (Po0.001) for the two doses, respectively, compared with placebo (additional antihypertensive agents other than ACE inhibitors and dihydropyridine CCBs were allowed). Regression to normoalbuminuria was significantly more frequent in the irbesartan 300 mg group (34% of patients) than in the placebo group (21%; P ¼ 0.006). On-treatment diastolic BP was similar in both irbesartan groups and the placebo group, but the average systolic BP was 3 mm Hg lower in the irbesartan 300 mg group than in the placebo group (P ¼ 0.004 for combined irbesartan groups vs placebo). Adjustment for BP levels did not alter the treatment effect of irbesartan. 58 The Appropriate Blood Pressure Control in Diabetes (ABCD) trial 42 compared the effects of intensive vs moderate BP control on diabetic complications, including renal function, over 5.3 years. Patients were randomized to treatment with enalapril or nisoldipine (intensive-control group) or placebo (moderate-therapy group). Overall, there were no differences in creatinine clearance between the moderate-and intensive-therapy groups or between the enalapril and nisoldipine groups. 42, 63 Among hypertensive patients, there was no difference in the secondary end point of UAER between the intensive-BP control and moderate-BP control groups. However, enalapril significantly reduced UAER during the first 3.5 years of the study (Po0.05) and remained numerically superior. 42 Among normotensive patients, intensive BP control reduced the incidence of the secondary end point of progression to microalbuminuria (P ¼ 0.012) and macroalbuminuria (P ¼ 0.028). 63 The authors suggested that it may be difficult to discern a RAASspecific effect when BP is well controlled. 63 Macroalbuminuria. ARB therapy has been consistently demonstrated to prevent or delay the progression of overt nephropathy and ESRD. 49, 57, 58 In the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, 57 losartan, when added to conventional antihypertensive therapy (most subjects also received amlodipine), reduced the risk of progression of nephropathy, assessed in terms of a doubling of serum creatinine, by 25% (P ¼ 0.006). The beneficial effects of ARB therapy were not impaired by the addition of a CCB. 57 ARB and CCB treatment were directly compared in IDNT. 49, 62 Irbesartan decreased the risk of doubling of serum creatinine by 37% compared with amlodipine (Po0.001) and by 33% compared with placebo (P ¼ 0.003). At 12 months, proteinuria decreased by 41, 11, and 16% in the ARB, CCB, and placebo groups, respectively. 49, 62 As mentioned previously, treatment that reduced proteinuria by half also reduced the risk of kidney failure by half in this time frame. 62 
Multifaceted approaches
Several studies have investigated the potential additional benefit of dual blockade of the RAAS with an ACE inhibitor and an ARB. In patients with
Evidence for renoprotection by blockade of the RAAS J Karalliedde and G Viberti microalbuminuria, a combination of an ACE inhibitor and an ARB was associated with greater reduction in BP (Pp0.02) and in the urinary albumin:creatinine ratio than monotherapy with either lisinopril 20 mg (P40.2) or candesartan 16 mg (P ¼ 0.04). 65 In the 12-month Candesartan and Lisinopril Microalbuminuria (CALM) II trial, however, no significant differences in systolic BP or albumin:creatinine ratio were seen when combination therapy of ACE inhibitor and ARB was compared with higher doses of the ACE inhibitor. 66 Another recent study followed 28 subjects with type I diabetes who had a BP p140/80 mm Hg with residual albuminuria (albumin:creatinine ratio 410 mg/mmol) while receiving the maximal recommended renal dose of lisinopril. 69 Candesartan or amlodipine was added to lisinopril for 24 weeks. Albuminuria fell to a similar extent in both groups, and BP was reduced, after adjusting for baseline differences, similarly by both candesartan and amlodipine. Interestingly, the fall in albumin:creatinine ratio was disproportionate to the decrease in systemic BP. 69 In clinical practice, combination antihypertensive therapy is often required to reach target BP levels. In patients already receiving an ACE inhibitor or ARB, recent evidence suggests that additional renoprotection may be provided by agents that block aldosterone. 70, 71 Studies of diuretics (alone or in combination with an ACE inhibitor) suggest possible renoprotective benefits. 64, 68 A low-dose combination of perindopril plus indapamide induced a greater decrease in UAER (À42%) than once-daily monotherapy with enalapril (À27%) in diabetic patients with hypertension and albuminuria. 68 This advantage remained after adjustment for the lower BP achieved by the combination group and for other factors. 68 Another study, Steno-2, applied a multifactorial approach to intensive vs conventional care and is the only recent study that has shown significant cardiovascular protection (reduction in risk of clinical cardiovascular events) in type II diabetes patients with microalbuminuria. 79 Treatments included behaviour modification and therapy for hyperglycaemia, hypertension (beginning with an ACE inhibitor or, if contraindicated, an ARB), dyslipidaemia, microalbuminuria, and aspirin for secondary cardiovascular prevention. During the 7.8-year trial, intensive treatment resulted in a relative risk reduction of 53% vs conventional treatment for the combined cardiovascular end point (P ¼ 0.008). 79 Importantly, this trial also established that regression of microalbuminuria is associated with a lower rate of GFR decline (Figure 2) . 80 
Clinical evidence of benefits of RAAS inhibition in non-diabetic renal disease
Controlled trials have also shown that drugs that inhibit the RAAS provide therapeutic benefits in patients with non-diabetic renal disease; representative trials evaluating a variety of agents are summarized in Table 3 . 43, 50, [81] [82] [83] [84] [85] [86] [87] [88] In a placebo-controlled trial, 3 years of benazepril therapy reduced the risk of the primary composite end point (doubling of serum creatinine or need for dialysis) by 53% compared with placebo (Po0.001). 50 A greater risk reduction was seen in patients with mild renal insufficiency (71%) compared with patients with moderate renal insufficiency (46%). Although both groups received add-on antihypertensive therapy to reach target BP levels, patients in the benazepril arm had lower BP than those in the placebo arm (a reduction of 3.5-5.0 mm Hg vs an increase of 0.2-1.5 mm Hg, respectively). Even after data were adjusted for changes in diastolic BP, however, the risk reduction associated with benazepril therapy was 38% overall, 66% in patients with mild insufficiency, and 26% in patients with moderate insufficiency. 50 Ramipril was shown to be renoprotective independent of its antihypertensive effect in a study of normotensive or hypertensive patients with overt proteinuria not related to diabetes. 81, 82 In this double-blind trial, BP control and the number of cardiovascular events were similar in the ramipril and placebo groups (patients received conventional antihypertensive therapy, excluding ACE inhibitors, in order to reach the target diastolic BP). In patients with baseline proteinuria X3 g/24 h, ramipril significantly slowed the decline in GFR per month. 81 Furthermore, the ACE inhibitor halved the risk of the combined secondary end point of doubling of serum creatinine or ESRD. Ramipril also significantly lowered urinary protein excretion by 23% at 1 month (Po0.01) to 55% at 36 months. This reduction exceeded what would have been expected from BP reduction alone. The investigators suggested that modification of glomerular protein traffic may be a renoprotective mechanism associated with ACE inhibition. 82 A meta-analysis of 11 randomized ACE inhibitor trials, predominantly in patients with non-diabetic Evidence for renoprotection by blockade of the RAAS J Karalliedde and G Viberti 89 ACE inhibitor regimens were associated with an important benefit (approximately 30% reduction in risk of ESRD or combined ESRD and doubling of serum creatinine) even after data were adjusted for greater decreases in BP in the ACE inhibitor groups. The benefits of ACE inhibitors were greater in patients with proteinuria. 89 Multifaceted aproaches Dual blockade of the RAAS was evaluated in the recent combination treatment of angiotensin II receptor blocker and ACE inhibitor in non-diabetic renal disease (COOPERATE) trial. 85 In this study, treatment with an ACE inhibitor plus an ARB was shown to be safe and effective in reducing the progression of renal disease. Aldosterone blockade with eplerenone may also provide potential benefit in non-diabetic renal disease. 86 Comparison of RAAS blockade with CCBs and b-blockers in non-diabetic renal disease Trials in non-diabetic nephropathy have consistently shown the benefits of RAAS blockade compared with other antihypertensive treatments, including CCBs and b-blockers. The African American Study of Kidney Disease and Hypertension AASK 43, 83 compared the effects of a b-blocker, an ACE inhibitor, and a dihydropyridine CCB on decline in GFR in subjects with hypertensive renal disease. The study also evaluated the effects of a low BP goal vs a 'conventional' BP goal. 43 The study did not find an association between BP level and the primary end point, but it did find a significant interaction between therapeutic group and risk. 43 Ramipril reduced the risk of the clinical composite outcome by 22% compared with metoprolol and by 38% compared with amlodipine. There was no significant difference between the amlodipine and metoprolol groups for the risk of the composite outcome. Both ramipril and metoprolol reduced the risk of ESRD alone and the risk of the combination of ESRD or death compared with amlodipine. 43 In subjects with overt proteinuria at baseline, the mean decline in GFR after 3 years was 36% slower in the ramipril group than in the amlodipine group (P ¼ 0.006). 83 In the Verapamil Versus Amlodipine in Nondiabetic Nephropathies Treated With Trandolapril (VVANNTT) study, 87 treatment with trandolapril significantly decreased proteinuria (P ¼ 0.018) vs baseline, but the addition of either amlodipine or verapamil did not provide any further decrease in proteinuria. REIN Evidence for renoprotection by blockade of the RAAS J Karalliedde and G Viberti
A post hoc analysis of renal outcomes in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) found no differences between chlorthalidone, amlodipine, or lisinopril in the rate of development of ESRD or a 50% decrease in GFR. 90 Participants assigned to amlodipine had a higher baseline GFR than those assigned to chlorthalidone, but rates of development of ESRD did not differ between the groups. 90 However, renal outcomes were not a primary end point in ALLHAT, and no proteinuria data were collected, which may confound interpretation of these results.
The second Ramipril Efficacy In Nephropathy trial (REIN-2) 88 compared conventional BP control with ramipril with intensified BP control with ramipril plus the CCB felodipine in patients with non-diabetic nephropathy. Despite an additional BP reduction with the CCB of 4/3 mm Hg (P ¼ 0.0019 and o0.0001, respectively), the hazard ratio for the primary end point, progression to ESRD, for intensified vs conventional control was 1.00 (95% confidence interval, 0.61-1.64; P ¼ 0.99). The authors concluded that the CCB provided no incremental benefit for patients already receiving the ACE inhibitor despite improved BP control. 88 However, because this was a relatively small study and had a limited follow-up period, the data must be interpreted with caution.
Optimal dosing and safety considerations with the use of RAAS inhibitors
Reduction of proteinuria is associated with improved outcome, 91 and it is important to note that the dose-response curves for BP and proteinuria differ. The greatest antiproteinuric efficacy of RAAS blockers is often observed at the highest tested dosage, which is frequently the upper end of their BP-dosing range. 92, 93 However, the optimal renoprotective doses of these agents has not yet been clearly established and is the subject of ongoing investigation. 93 When initiating either an ACE inhibitor or an ARB-especially in patients with renal impairment-it is important that several safety considerations are addressed and that patients are monitored closely for adverse effects. 94 
Conclusion
The increasing incidence of diabetes mellitus and hypertension amplifies the risk of ESRD. Lowering BP alleviates haemodynamic damage, and RAAS blockade ameliorates both haemodynamic and nonhaemodynamic mechanisms of renal damage. The goal of therapy, therefore, is BP control combined with maximized end-organ protection. Tight BP control has been shown to provide greater cardiorenal protection than less rigorous control, affirming the crucial role of hypertension in diabetic and nondiabetic kidney disease.
However, BP reduction alone is insufficient for maximal renal protection. Accumulating evidence indicates that, in addition to their proven BPlowering efficacy, ACE inhibitors and ARBs are effective in preventing or delaying progression of microalbuminuria and thereby inhibiting the progression towards overt nephropathy as well as delaying the onset of ESRD in patients with renal impairment. These beneficial renoprotective effects have been seen in diabetic and non-diabetic patients and in hypertensive and normotensive patients.
